Acta Angiologica最新文献_第2页

Irisin — the future of ischemic stroke therapy? 鸢尾素——缺血性中风治疗的未来?

Acta Angiologica Pub Date : 2023-03-30 DOI: 10.5603/aa.2023.0006

Magda Grześkiewicz, Joanna Elżbieta Kobak, Hubert Drewniak, Piotr Terlecki, Stanisław Przywara

{"title":"Irisin — the future of ischemic stroke therapy?","authors":"Magda Grześkiewicz, Joanna Elżbieta Kobak, Hubert Drewniak, Piotr Terlecki, Stanisław Przywara","doi":"10.5603/aa.2023.0006","DOIUrl":"https://doi.org/10.5603/aa.2023.0006","url":null,"abstract":"Irisin is a recently discovered hormone, synthesized mainly by the muscles. Expression of irisin and its precursor named FNDC5 was also found in the heart, kidneys, liver, pancreas, adipose tissue, and brain including cortical neurons, hippocampus, cerebellum, hypothalamus, and spinal cord. The purpose of this study is to review the latest research on the properties of the irisin and its cytoprotective effect against neuronal damage and to draw attention to its possible clinical use in the treatment of stroke. Notch pathway activity increases after ischemic damage, stimulating the repair of the affected brain area. Irisin activates the Notch pathway which inhibits the activity of microglia, secretion of inflammatory factors, and finally leads to reduction of the brain edema. Studies revealed that irisin increases levels of brain-derived neurotrophic factor (BDNF), leading to enhancement of survival and migration of the neurons, and protecting nerve cells from damage during the ischemic stroke. It was also found that irisin maintains mitochondrial integrity, reduces oxidative stress, and exerts a protective effect on the blood-brain barrier. Irisin entails a neuroprotective effect, reducing the extent of the infarcted area and the degree of brain damage. Stimulation of the irisin expression by physical activity or its exogenous administration remains the subject of research that raises hope for development of the new therapeutic options for diseases, especially ischemic stroke.","PeriodicalId":41754,"journal":{"name":"Acta Angiologica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135419803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leukotrienes in the atherosclerotic cardiovascular diseases — a systematic review 动脉粥样硬化性心血管疾病中的白三烯——系统综述

IF 0.2

Acta Angiologica Pub Date : 2022-12-30 DOI: 10.5603/aa.2022.0013

A. Wachsmann-Maga, M. Kaszuba, M. Maga, A. Włodarczyk, J. Krężel, P. Kaczmarczyk, Katarzyna Bogucka, P. Maga

引用次数: 4

Fenestration and duplication of contralateral internal jugular veins with concomitant cerebral arteries malformations 伴发脑动脉畸形的对侧颈内静脉开窗和重复

IF 0.2

Acta Angiologica Pub Date : 2022-12-30 DOI: 10.5603/aa.2022.0018

Mateusz Winder, J. Pilch-Kowalczyk

引用次数: 0

Severe acute kidney injury after pharmacomechanical thrombectomy for acute limb ischemia 药物力学取栓治疗急性肢体缺血后严重急性肾损伤

IF 0.2

Acta Angiologica Pub Date : 2022-12-30 DOI: 10.5603/aa.2022.0016

P. Brazis, P. Wierzchowski, A. Migdalski, A. Jawień

引用次数: 0

Comparison between unfractionated heparin (UFH) and fondaparinux on platelets and D-dimer level in COVID-19 patients with hypercoagulation 普通肝素（UFH）和磺达肝素对新冠肺炎高凝患者血小板和D-二聚体水平的比较

IF 0.2

Acta Angiologica Pub Date : 2022-12-30 DOI: 10.5603/aa.2022.0015

Meity Ardiana, H. Hermawan, P. M. Harsoyo, I. Sufiyah, M. Fanani

{"title":"Comparison between unfractionated heparin (UFH) and fondaparinux on platelets and D-dimer level in COVID-19 patients with hypercoagulation","authors":"Meity Ardiana, H. Hermawan, P. M. Harsoyo, I. Sufiyah, M. Fanani","doi":"10.5603/aa.2022.0015","DOIUrl":"https://doi.org/10.5603/aa.2022.0015","url":null,"abstract":"Introduction: This study aimed to compare the clinical effects between UFH and fondaparinux in COVID-19 patients with hypercoagulation. Material(s) and Method(s): This was a prospective cohort study. Samples were taken consecutively from hospitalized COVID-19 patients with hypercoagulation who received UFH or fondaparinux based on the standardized guidelines. A total of 71 patients met the inclusion criteria. Patients were evaluated for platelet and D-dimer values before and after administration of UFH or fondaparinux. Result(s): Although there was no difference in D-dimer reduction between the two groups (p = 0.44), fondaparinux showed a greater reduction, 26% against 22% for UFH. While on platelets, there was a significant difference (p = 0.04) between fondaparinux and UFH. Fondaparinux showed a reduced thrombocytopenia impact, as seen by an increase in pre-and post-therapy platelets of up to 50%, compared to 16% in UFH. In regard to the incidence of Heparin-Induced Thrombocytopenia (HIT), there was no significant difference between post-UFH therapy and post-fondaparinux therapy (p = 0.361). Conclusion(s): Fondaparinux did not reduce platelet levels as much as UFH, but there was no difference between the fondaparinux group compared to the UFH group in the effect of decreasing D-dimer levels and the sign of HIT. Copyright © 2022 Via Medica.","PeriodicalId":41754,"journal":{"name":"Acta Angiologica","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48978911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Standing waves in a patient with systemic scleroderma 系统性硬皮病患者的驻波

IF 0.2

Acta Angiologica Pub Date : 2022-12-30 DOI: 10.5603/aa.2022.0017

M. Wysocki, A. Szuba, Jędrzej Fischer

{"title":"Standing waves in a patient with systemic scleroderma","authors":"M. Wysocki, A. Szuba, Jędrzej Fischer","doi":"10.5603/aa.2022.0017","DOIUrl":"https://doi.org/10.5603/aa.2022.0017","url":null,"abstract":"Standing waves are a very rare angiographic image with an unclear etiology. Many theories have been developed to explain this phenomenon, but none have been confirmed. We present an interesting case of a 57-year-old woman, whose angiography showed standing waves along the entire length of the superficial femoral artery. On admission, the patient's general condition was fairly good. No significant abnormalities were observed in the P-A chest feet and hands X-ray, as well as in the ultrasound of the abdominal cavity and pelvis. On March 8, the patient underwent angiography documenting the presence of regular \"goose trachea-like\" 'notched walls' over the entire length of the right superficial femoral artery. Angiography was then followed by an ultrasound exam of femoral arteries, however, no femoral artery wall changes were seen. The diagnosis was standing waves. Moreover, extensive diagnostics for systemic disease, as well as the overall clinical picture allowed for the diagnosis of systemic scleroderma. Standing waves are a rare phenomenon, harmless to the patient's life and health. Researchers have put forward many theories to explain its unclear etiology. The presence of standing waves has also been reported with the coexistence of diseases such as Buerger's, Tolos-Hunt's, or rheumatic heart disease. Moreover, it is worth mentioning the possibility of misdiagnosing standing waves as FMD. To summarize, standing waves are a harmless phenomenon. Despite its rare occurrence, it is worth remembering not to misdiagnose it and consequently, implement unnecessary diagnostics and treatment and cause superfluous anxiety in the patient. Copyright © 2022 Via Medica.","PeriodicalId":41754,"journal":{"name":"Acta Angiologica","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41856823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In-hospital diagnostic strategies for acute pulmonary embolism — results of a single-center study based on the experience of a multi-profile clinical hospital 急性肺栓塞的院内诊断策略——基于多专科临床医院经验的单中心研究结果

IF 0.2

Acta Angiologica Pub Date : 2022-12-30 DOI: 10.5603/aa.2022.0014

Urszula Szymańska, M. Kurzyna, P. Kułak, D. Kosior

引用次数: 0

Wytyczne Europejskiego Towarzystwa Chirurgii Naczyniowej (ESVS) w zakresie diagnostyki i leczenia tętniaków aorty brzusznej i tętnic biodrowych — wersja 2019

IF 0.2

Acta Angiologica Pub Date : 2022-11-22 DOI: 10.5603/aa.2022.0012

Anders Wanhainen, Fabio Verzini, Isabelle Van Herzeele, Eric Allaire, Matthew Bown, Tina Cohnert, Florian Dick, Joost van Herwaarden, Christos Karkos, Mark Koelemay, Tilo Kölbel, Ian Loftus, Kevin Mani, Germano Melissano, Janet Powell, Zoltán Szeberin

引用次数: 0

Commentary to the guidelines: “Guidelines on the prevention and treatment of venous thromboembolism in cancer patients treated surgically, including patients under 18 years of age” 对指南的评论:《手术治疗的癌症患者静脉血栓栓塞的预防和治疗指南，包括18岁以下患者》

IF 0.2

Acta Angiologica Pub Date : 2022-08-16 DOI: 10.5603/aa.2022.0006

Z. Krasiński, B. Krasińska

引用次数: 0

Deep vein thrombosis of the lower limbs in injection drug users: case series 注射吸毒者下肢深静脉血栓形成病例系列

IF 0.2

Acta Angiologica Pub Date : 2022-08-16 DOI: 10.5603/aa.2022.0007

Jędrzej Fischer, W. Kwiatkowska, W. Witkiewicz

引用次数: 0